Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

Breast Cancer Res. 2021 Jan 7;23(1):6. doi: 10.1186/s13058-020-01384-6.

Abstract

Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpins their characteristic discohesive growth pattern, with cells arranged in single file and dispersed throughout the stroma. Typically, tumours are luminal in molecular subtype, being oestrogen and progesterone receptor positive, and HER2 negative. Since last reviewing the lobular literature (McCart Reed et al., Breast Cancer Res 17:12, 2015), there has been a considerable increase in research output focused on this tumour type, including studies into the pathology and management of disease, a high-resolution definition of the genomic landscape of tumours as well as the evolution of several potential therapeutic avenues. There abounds a huge amount of new data, which we will review herein.

Keywords: Genomics; ILC; LCIS; Lobular; Lobular breast cancer; Lobular neoplasia; Pathology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / etiology
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy
  • Carcinoma, Lobular / diagnosis*
  • Carcinoma, Lobular / etiology
  • Carcinoma, Lobular / mortality
  • Carcinoma, Lobular / therapy
  • Diagnosis, Differential
  • Disease Progression
  • Disease Susceptibility
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Expression
  • Genomics / methods
  • Humans
  • Mutation
  • Neoplasm Grading
  • Neoplasm Staging
  • Phenotype
  • Prognosis
  • Tumor Microenvironment

Substances

  • Biomarkers, Tumor